Ignite Creation Date:
2024-05-06 @ 6:45 PM
Last Modification Date:
2024-10-26 @ 2:54 PM
Study NCT ID:
NCT05770713
Status:
COMPLETED
Last Update Posted:
2023-04-21
First Post:
2023-03-05
Brief Title:
A Real-life Study to Learn About the Use and Effects of the CDK46 Inhibitors in Canadian Patients With Breast Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Treatment Patterns And Clinical Outcomes Among Patients Receiving CDK46 Inhibitors Combinations For HRHER2- AdvancedMetastatic Breast Cancer In A Canadian Real World Setting
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
CDK46 inhibitors are approved medicines indicated for the treatment of a kind of advancedmetastatic breast cancer called hormone receptors positive HR Human epidermal growth factor receptor 2 negative HER2- disease They are given orally in combination with hormonal therapies
The purpose of this study is to better understand how the CDK46 inhibitors combinations are used in real-life conditions and their clinical impact for the treatment of Canadian patients affected by HR HER2- advanced breast cancer ABC or metastatic breast cancer MBC
Female patients aged 18 years old or more presenting the following conditions will be selected for the study
HRHER2- breast cancer diagnosis with confirmed metastatic or advanced disease
Diagnosis of ABCMBC between 01 January 2016 and 01 July 2021
Treatment with CDK46 inhibitor
Information will be collected from one single Canadian institution on each selected real-life patient treated with CDK46 inhibitors
The purpose of this study is to better understand how the CDK46 inhibitors combinations are used in real-life conditions and their clinical impact for the treatment of Canadian patients affected by HR HER2- advanced breast cancer ABC or metastatic breast cancer MBC
Female patients aged 18 years old or more presenting the following conditions will be selected for the study
HRHER2- breast cancer diagnosis with confirmed metastatic or advanced disease
Diagnosis of ABCMBC between 01 January 2016 and 01 July 2021
Treatment with CDK46 inhibitor
Information will be collected from one single Canadian institution on each selected real-life patient treated with CDK46 inhibitors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None